Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.69) per share. This is a 6.15 percent decrease over losses of $(0.65) per share from the same period last year.
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $143 to $154.